Trials / Completed
CompletedNCT00759174
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 673 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- Male
- Age
- 45 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this non-interventional study is to examine whether use of Phosphodiesterase Inhibitors (PDE5s), including use of sildenafil, vardenafil, or tadalafil, triggers the onset of acute NAION.
Detailed description
Sites will identify patients who meet the entry criteria during the conduct of their normal practice. Patients meeting these criteria will be offered participation in the study after reading and completing an informed consent document.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | No intervention | No intervention occurs in this observational study. |
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2012-10-01
- Completion
- 2012-10-01
- First posted
- 2008-09-25
- Last updated
- 2021-02-01
- Results posted
- 2013-10-17
Locations
105 sites across 6 countries: United States, France, Germany, Italy, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT00759174. Inclusion in this directory is not an endorsement.